Salvage treatment with anlotinib for advanced non‐small cell lung cancer

Salvage treatment with anlotinib for advanced non‐small cell lung cancer

Background This real‐world study assessed the efficacy and toxicity of anlotinib as salvage treatment in Chinese patients with advanced non‐small cell lung cancer (NSCLC). Methods The medical records of 81 patients with advanced NSCLC who had failed at least two lines of chemotherapy were retrospect...

Full description

Bibliographic Details
Main Authors: Di Wu, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Xiaoling Chen, Xiangjuan Ma, Guangming Tian, Jindi Han, Sen Han, Jieran Long, Yang Wang, Ziran Zhang, Jian Fang
Format: Article
Language:English
Published: Wiley 2019-07-01
Series:Thoracic Cancer
Subjects:
Angiogenesis inhibitor
anlotinib
efficacy
non‐small cell lung cancer
Online Access:https://doi.org/10.1111/1759-7714.13120

Internet

https://doi.org/10.1111/1759-7714.13120

Similar Items